Merit Medical Systems stock has delivered a 29.4% return over the past 5 years, while its current checks send mixed signals as the Discounted Cash Flow (DCF) intrinsic value suggests upside and market multiples point to a richer price tag.

• Over the last 5 years, Merit Medical Systems has returned 29.4%, which puts recent short term swings into a longer term context for investors assessing value.
• Recent positive reactions to upgraded company expectations can support higher valuation assumptions. However, any disappointment on future earnings or cash flow delivery may quickly pressure the current share price.
• The stock scores 3 out of 6 on the valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Merit Medical Systems' current share price of US$85.53 offers enough upside relative to the DCF based intrinsic value estimate to justify the risks that come with the higher readings on traditional valuation multiples.

Is Merit Medical Systems Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Merit Medical Systems is worth based on the cash it can generate for shareholders. On this approach, the latest twelve month free cash flow is about $219.4 million, with the model assuming growing cash flows rather than a sharp step change or decline over the next decade.

Those projections translate into an intrinsic value of about $118 per share, compared with the current share price of $85.53. That implies Merit Medical Systems trades at roughly a 27.3% discount to the cash flow based estimate. Because the company recently raised full year guidance after a strong quarter, the current price still sits below what the DCF suggests despite the improved outlook already being in focus.

On this cash flow view, the stock currently appears undervalued relative to its estimated intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests Merit Medical Systems is undervalued by 27.3%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Is Merit Medical Systems Getting Expensive on Earnings?

P/E is a useful cross check for Merit Medical Systems because earnings are a key focus for many healthcare investors. The stock trades on a P/E of about 35.1x, which is above the Medical Equipment industry average of roughly 29.0x and below the peer group average of around 46.8x.

The fair P/E ratio implied for Merit Medical Systems by the model is about 24.4x, based on factors such as its sector, size and risk profile. Compared with the current 35.1x, the market is asking investors to pay a higher price for each dollar of earnings than this framework suggests. Even with stronger recent earnings and higher guidance already reflected in sentiment, the current P/E indicates that the stock is priced at a premium to the tailored fair multiple.

On this P/E measure, Merit Medical Systems stock appears overvalued relative to the earnings multiple the model considers reasonable.

The Merit Medical Systems Narrative: What Would Justify Today's Price?

Simply Wall St Narratives give you a structured way to connect Merit Medical Systems' valuation puzzle to specific expectations about its future. Each Narrative explains what would need to happen to Merit Medical Systems' growth, margins and earnings for the stock to be worth materially more or less than it is today. It also links that view to a clear set of assumptions about growth, profitability and risk that you can revisit as new information comes through on the Community page.

Community views on Merit Medical Systems sit on a wide spectrum, from a meaningful upside story to a case that sees little valuation cushion.

Bull case: 22% undervalued

"Merit’s focus on higher margin platforms such as oncology, endoscopy, cardiac therapies and vascular intervention, supported by tuck in acquisitions like Biolife, C2 CryoBalloon and View Point that have strong gross margin profiles, is designed to shift the mix toward therapeutic products and support non GAAP gross margin and operating margin improvement over time…"

Bear case: roughly fairly valued

"Although the company outlines long term product platforms in areas such as vascular intervention, cardiac therapies, renal therapies and OEM, and references multiyear growth and profitability targets under CGI, execution on product launches, recalls in renal and OEM order volatility could weigh on revenue growth and keep operating margins closer to current levels rather than expanding quickly…"

Do you think there's more to the story for Merit Medical Systems? Head over to our Community to see what others are saying!

The Bottom Line

For Merit Medical Systems, the Discounted Cash Flow (DCF) intrinsic value estimate points to undervaluation, while the P/E view suggests the stock is priced at a premium to its earnings. The split comes from what each lens focuses on. The intrinsic value view leans on the timing and durability of future cash flows, while the higher multiple reflects current growth expectations and sentiment in its peer group. The key question from here is whether Merit Medical Systems can deliver the margin and earnings progress needed to keep justifying that richer multiple and close the gap with its intrinsic value estimate.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.